CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response

Kuhn, Nicholas F.; Purdon, Terence J.; Leeuwen, Dayenne G. van; Lopez, Andrea V.; Curran, Kevin J.; Daniyan, Anthony F.; Brentjens, Renier J.

doi:10.1016/j.ccell.2019.02.006

Cited by 161 publications

(157 citation statements)

References 58 publications

Supporting

Mentioning

153

Contrasting

Order By: Relevance

“…IL-12 is one of the most powerful anti-cancer cytokines and can act through pleiotropic effects on both innate and acquired immune cells to remodel the tumor micro-environment. A similar idea has been reported for CAR T cells that secrete IL-18 and HVEM [47], or CD40 ligand [48]. Recently, there has also been a report from CAR that emphasizes the function of a drug "carrier" to improve the microenvironment rather than the cytotoxicity of CAR T cells.…”

Section: Armored Car T Cellssupporting

confidence: 60%

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Hosen

2019

Cancers

View full text Add to dashboard Cite

CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma. Many researchers are now trying to develop CAR T cells for various types of cancer. For multiple myeloma (MM), B-cell maturation antigen (BCMA) has been recently proved to be a promising target. However, cure of MM is still difficult, and several other targets, for example immunoglobulin kappa chain, SLAM Family Member 7 (SLAMF7), or G-protein coupled receptor family C group 5 member D (GPRC5D), are being tested as targets for CAR T cells. We also reported that the activated integrin β7 can serve as a specific target for CAR T cells against MM, and are preparing a clinical trial. In this review, we summarized current status of CAR T cell therapy for MM and discussed about the future perspectives.

show abstract

Section: Armored Car T Cellssupporting

confidence: 60%

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Hosen

2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Immune system mobilization is important for tumor elimination . Since the tumor microenvironment negatively impacts the immune response, strategies aimed at reversing immunosuppression induced by tumors have been developed including immune checkpoint blockade and chimeric antigen receptor T cell therapy . However, the efficiency of these strategies varies from one person to the other and the immune cell‐based vaccine therapies are very expensive .…”

Section: Discussionmentioning

confidence: 99%

Expression levels of a gene signature in hiPSC associated with lung adenocarcinoma stem cells and its capability in eliciting specific antitumor immune‐response in a humanized mice model

Wang

Shao

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

Background: Previous studies have reported that cancer stem cells (CSCs) play a key role in tumorigenesis, metastasis, and recurrence. CSC-based vaccination confers better protection in tumor cells. However, isolation and cultivation of CSCs are difficult. This study aimed to explore the similarities between CSCs and induced pluripotent stem cells (iPSCs). Methods: ALDH1+ cancer stem cells were isolated from lung adenocarcinoma patients and their gene expression patterns compared with human induced pluripotent stem cells (hiPSCs). In addition, a tumor vaccine was developed using hiPSC and unmethylated cytosine-guanine (CpG). Finally, the antitumor properties of the vaccine were evaluated in a humanized mouse model. Results: Preimmunization of iPSC+CpG elicited stronger antigen presentation and cytotoxic T cell response which suppressed the growth of tumors. Adoptive transfer of spleen T cells from the vaccine preimmunized mice inhibited tumor growth in unvaccinated recipients without any side effects. Conclusions: This study suggests a universal strategy for tumor therapy which simplifies future clinical procedures. Therefore, the application of hiPSC elicits tumor protective responses.

show abstract

“…These CARs were capable of credentialing host antigen-presenting cells (APCs) to prime endogenous T cells against a variety of unidentified tumor antigens, circumventing antigen loss variants. 41 One of the largest lessons learned from studies with ALT has been the antitumor benefit obtained with myeloconditioning prior to adoptive transfer. 21,60 Lymphodepletion using total body irradiation or high-dose chemotherapy in mice and humans has leveraged the induction of cytokines and consequent homeostatic T-cell proliferation.…”

Section: Glioma-associated Antigens Currently Identified Includementioning

confidence: 99%

The current state of immunotherapy for gliomas: an eye toward the future

Fecci

Sampson

2019

Journal of Neurosurgery

View full text Add to dashboard Cite

The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.

show abstract

CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response

Cited by 161 publications

References 58 publications

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Expression levels of a gene signature in hiPSC associated with lung adenocarcinoma stem cells and its capability in eliciting specific antitumor immune‐response in a humanized mice model

The current state of immunotherapy for gliomas: an eye toward the future

Contact Info

Product

Resources

About